So the way I read the timing; the second and third cohorts start roughly halfway through the previous cohort after the 21 day safety review. My math is that the fastest time in which the trial will be complete is 3 months. That is assuming all subjects start at the same time, no one drops out, the next cohort starts immediately after the 21 day safety reviews, and no delays. So realistically this is probably a 5 month trial. Still super fast to get to final results with the benefit of receiving intermediate data throughout the trial. I have a feeling that as long as B-UP is working well the new president is going to have PRs similar to today's lined up to drop on the shorts at very appropriate times through the next few months.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links